Published in final edited form as:

Behav Genet. 2016 September ; 46(5): 608–626. doi:10.1007/s10519-016-9800-8.

A Test-Replicate Approach to Candidate Gene Research on Addiction and Externalizing Disorders: A Collaboration across Five Longitudinal Studies

Diana R. Samek^a, Jennifer Bailey^b, Karl G. Hill^b, Sylia Wilson^d, Susanne Lee^c, Margaret A. Keyes^d, Marina Epstein^b, Andrew Smolen^e, Michael Miller^d, Ken C. Winters^f, J. David Hawkins^b, Richard F. Catalano^b, William G. Iacono^d, and Matt McGue^d

^aDepartment of Human Development and Family Studies, Auburn University, Auburn, Alabama

^bSchool of Social Work, University of Washington, Seattle, Washington

^cDepartment of Psychiatry, University of Minnesota, Minneapolis, Minnesota

^dDepartment of Psychology, University of Minnesota, Minneapolis, Minnesota

^eInstitute for Behavior Genetics, University of Colorado, Boulder, Colorado

^fWinters Consulting Group, Minneapolis, MN

Abstract

This study presents results from a collaboration across five longitudinal studies seeking to test and replicate models of gene-environment interplay in the development of substance use and externalizing disorders (SUDs, EXT). We describe an overview of our conceptual models, plan for gene-environment interplay analyses, and present main effects results evaluating six candidate genes potentially relevant to SUDs and EXT (MAOA, 5-HTTLPR, COMT, DRD2, DAT1, and DRD4). All samples included rich longitudinal and phenotypic measurements from childhood/adolescence (ages 5–13) through early adulthood (ages 25–33); sample sizes ranged from 3,487 in the test sample, to ~600–1000 in the replication samples. Phenotypes included lifetime symptom counts of SUDs (nicotine, alcohol and cannabis), adult antisocial behavior, and an aggregate externalizing disorder composite. Covariates included the first 10 ancestral principal components computed using all autosomal markers in subjects across the data sets, and age at the most recent assessment. Sex, ancestry, and exposure effects were thoroughly evaluated. After correcting for

Correspondence concerning this article should be addressed to Diana R. Samek, 203 Spidle Hall, Auburn, AL 36849, di.samek@gmail.com, phone: (334) 844-3173.

Conflict of Interest

All authors declare no conflict of interest. Specifically, Diana R. Samek declares no conflict of interest. Jennifer Bailey declares no conflict of interest. Karl G. Hill declares no conflict of interest. Sylia Wilson declares no conflict of interest. Susanne Lee declares no conflict of interest. Margaret A. Keyes declares no conflict of interest. Marina Epstein declares no conflict of interest. Andrew Smolen declares no conflict of interest. Michael Miller declares no conflict of interest. Ken C. Winters declares no conflict of interest. J. David Hawkins declares no conflict of interest. Richard F. Catalano declares no conflict of interest. William G. Iacono declares no conflict of interest. Matt McGue declares no conflict of interest.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed Consent

Informed consent was obtained from all individual participants included in the study.

multiple testing, only one significant main effect was found in the test sample, but it was not replicated. Implications for subsequent gene-environment interplay analyses are discussed.

Keywords

Addiction; Alcohol; Candidate Gene Studies; Cannabis; Externalizing Disorders; Nicotine; Replication Studies; Substance Use Disorders

Since the early 2000s, research into candidate gene-environment interactions involved in psychiatric disorders has been both exciting (Caspi et al. 2002; Caspi et al. 2003) and contentious (Chabris et al. 2012; Duncan and Keller 2011; Risch et al. 2009). A landmark paper published in *Science* and subsequent replication attempts illustrates this well. Caspi and colleagues (2003) showed that a specific genetic variant (the 5-HTTLPR serotonin transporter) was associated with an increased likelihood for depression, but only for those who had experienced rather severe stressful life events (e.g., childhood maltreatment). Such findings resonated with diathesis stress theory (e.g., Monroe and Simons, 1991) as well as general theories of individual-environment interplay (Bronfenbrenner and Ceci 1994; Sameroff and Mackenzie 2003) and generated excitement across a variety of social science and biological fields. However, subsequent meta-analyses have contributed to a continuing debate on the validity of the candidate gene-environment effect. The meta-analysis by Risch and colleagues (2009) did not replicate this association, and similar null or negligible effects were reported by an independent group (Munafo et al. 2009). However, another subsequent meta-analysis of 54 studies published in 2011 *did* find evidence for the gene-environment interaction (Karg et al. 2011). This body of work brings to light the need for replication of novel findings.

The validity of the original Caspi et al. (2003) finding and the positive meta-analytic finding is still hotly debated. Critical attention has been paid to the fact that the inclusion of only published articles (or in press or in review articles) in meta-analytic reviews increases vulnerability to publication bias (i.e., the difficulty of publishing null results; Duncan and Keller 2011; Duncan et al. 2014). To thoroughly test this, Duncan and Keller (2011) conducted an extensive review of all published candidate gene-environment interaction studies ($N = 103$) relevant to psychiatric traits (covering 2000 to 2009). They found that while nearly all novel candidate gene-environment interaction studies were significant, only about a quarter of replication attempts reached significance. Furthermore, power calculations showed the sample sizes necessary to reach statistical significance for the kinds of small effect sizes expected reaches well into the thousands, and many of the previously published studies reporting significant effects appeared to be vastly underpowered. Due to this, many of the published candidate gene results were hypothesized to be false positives (also see Dick et al. 2015; Duncan et al. 2014).

In response to these issues, replication has become the gold standard in any evaluation of candidate gene analysis and many respected journals have specific editorial policies concerning replication involving candidate gene work (c.f. Hewitt 2012; Johnston et al. 2013; Lesch 2014; Munafo and Gage 2013). Further, researchers have noted the need for replication studies that include not only the same genetic markers, but also similar measures

of environmental risk and phenotypes of interest (Duncan and Keller 2011; Rutter 2012). In response to such calls, the present paper reports results from an on-going collaboration between five longitudinal studies investigating the etiology of substance use disorders (SUDs) and related psychopathology through models of complex gene- and person-environment interplay. The five longitudinal studies involved include two studies from the Minnesota Center for Twin and Family Research (MCTFR), specifically the Minnesota Twin and Family Study (MTFS; Iacono et al. 1999) and the Sibling Interaction and Behavior Study (SIBS; McGue et al. 2007), the Minnesota Drug Abuse and Attention-Deficit Hyperactivity Disorder study (MN ADHD; Winters 2015), and two studies from the Social Development Research Group, including the Seattle Social Development Project (SSDP; Hawkins et al. 2003; Hill et al. 2010), and the Raising Healthy Children study (RHC; Brown et al. 2005; Catalano et al. 2003; Haggerty et al. 2006). All five of the studies included in the collaboration are longitudinal studies of child/adolescent through young adulthood development, focusing specifically on the etiology or the general risk and protective factors associated with substance use problems and related psychopathology. The studies were selected because they include highly similar phenotype and environment measures, increasing their utility in terms of replication of findings.

Conceptual Model Guiding Our On-Going Collaboration

Our groups began to work together in response to a call for collaborative research on longitudinal gene-environment interplay issued by the National Institute on Drug Abuse (The Genes, Environment, and Development Initiative, RFA-DA-07-012). Early in our work, a conceptual model was proposed by Bailey et al. (2011), to evaluate models of candidate gene-environment interaction in a general/specific framework. Specifically, Bailey and colleagues evaluated a phenotypic model which attended both to general externalizing problems in early adulthood as the shared variance between nicotine dependence, alcohol, and illicit drug use, antisocial behavior, sexual risk, and crime, and to the specific (unique) variance of each of these outcomes. In addition, the approach modeled general and specific environmental factors predictive of these outcomes. For example, the general family environment latent variable was measured using reports of general parent-child relationship quality and parenting practices (e.g., conflict, management), family tobacco-specific environments were measured by parent and sibling smoking during the child's adolescence, and family alcohol-specific environment was measured by parent and sibling drinking during the child's adolescence. Bailey et al. showed clear evidence linking the general family environment with the estimated latent variable of general externalizing problems (i.e., the poorer the family environment in adolescence, the greater the likelihood for externalizing problems in early adulthood), as well as evidence linking tobacco-specific and alcohol-specific family environments to unique variance in nicotine dependence and alcohol use disorder (i.e., the more parents and siblings smoked or drank during the target's adolescence, the greater the likelihood for nicotine dependence and alcohol use disorder for the target in early adulthood, after accounting for any variance shared between adult nicotine dependence and alcohol use disorder with externalizing problems in general).

In the 2011 publication, Bailey and colleagues proposed that the phenotypic model could be further adapted to include candidate genes or polygenic risk scores to evaluate for gene-

environment interplay. Candidate genes or polygenic risk scores related to dopamine regulation, for example, could be evaluated as predictors of the latent factor of adult externalizing and substance use problems (reflecting genetic main effects), as correlates of the adolescent family environments (demonstrating gene-environment correlation), and/or as moderators of the association between general adolescent family environment and the latent factor of adult externalizing and substance use problems (demonstrating gene-environment interaction).

We have now replicated this basic phenotypic model in several data sets (Bailey et al. 2014; Samek et al. 2014) and at different developmental stages (Epstein et al. 2013). We have shown consistent evidence linking the general adolescent family environment (e.g., low parent-child conflict, high management) to the general externalizing latent factor in later adulthood – with a moderate effect size (i.e., the poorer the general family environment in adolescence, the greater the likelihood for externalizing problems in adulthood). There has been less consistent evidence linking the unique adolescent family smoking and drinking environments to unique variance in adult nicotine dependence and alcohol use disorder (Bailey et al. 2014; Samek et al. 2014), thus one effort is now focused on evaluating more complex patterns of gene-environment interplay relevant to the general pathway rather than substance-specific pathways. In addition, we are developing potential measures of general and drug-specific genetic influence for inclusion in this model.

Candidate Gene Review

The six candidate genes chosen for this work (MAOA, 5-HTTLPR, COMT, DRD2, DAT1, DRD4) are likely the most extensively studied candidate genes in relation to SUD and externalizing problems broadly that were available for analysis across our five studies. Table 1 lists the six candidate genes, gives an overview of their functions and coding, and cites meta-analyses supporting associations between the candidate genes and externalizing and substance use outcomes. We briefly review each candidate gene and its supporting meta-analytic literature, although caution should be warranted in interpreting even these meta-analytic results given the concerns we have outlined above (see Dick et al. 2015; Duncan and Keller 2011; Duncan et al. 2014).

MAOA and 5-HTTLPR are probably the most well-known and widely studied candidate genes, likely due in part to earlier work by Caspi and colleagues (2002, 2003). As shown in Table 1, MAOA is involved in the deamination of several neurotransmitters relevant to substance use and externalizing problems, including serotonin, dopamine, norepinephrine, and epinephrine. The MAOA gene is located on the X-chromosome (Xp11.23–11.4), whose variants arise from a sequence of DNA that is repeated in tandem; the number of repetitions or “repeats” varies (2 to 5 repeats) among individuals. This type of polymorphism is called a variable number of tandem repeats (VNTR). For MAOA, alleles containing 2 or 3 repeats are considered the “risk alleles”, i.e., the variant that is more likely to be associated with externalizing problems relative to the “long allele” or the variant with the longer number of repeats. Similarly, 5-HTTLPR is another VNTR (or 43 base-pair insertion/deletion), where the allele with the short number of repeats is considered to be the risk allele.

Several meta-analyses have evaluated the association between MAOA and antisocial behavior, including MAOA as a moderator of the link between childhood maltreatment and adult antisocial behavior (see Byrd and Manuck 2014; Ficks and Waldman 2014; Kim-Cohen et al. 2006; Reif et al. 2014). Several meta-analyses have also looked at 5-HTTLPR and its relationship to antisocial behavior and other psychiatric outcomes (e.g., Ficks and Waldman 2014; Karg et al. 2011; Miller et al. 2013, and as discussed above). For example, Ficks and Waldman (2014) conducted a meta-analysis on studies evaluating the association between both MAOA and 5-HTTLPR with antisocial behavior and found evidence of small but significant effects (31 total studies included for MAOA, pooled $OR = 1.08$; 18 total studies included for 5-HTTLPR, pooled $OR = 1.41$). Moreover, in their meta-analysis of 27 peer-reviewed papers, Byrd and Manuck (2014) showed evidence of a significant MAOA x childhood maltreatment effect on antisocial behavior for males, but not females, consistent with an earlier meta-analysis by (Kim-Cohen et al. 2006). Byrd and Manuck also demonstrated a small main effect of MAOA on antisocial behavior for females.

There has been comparatively less research on COMT and the dopamine candidate genes (DRD4, DAT1, DRD2) in relation to SUDs or antisocial behavior. Like MAOA and 5-HTTLPR, DAT1 and DRD4 are VNTRs (the shorter number of repeats is the “risk” allele for DAT1, the longer number of repeats is the “risk” allele for DRD4 – see Table 1 for details). COMT (rs4680) and DRD2 (rs1800497) are single nucleotide polymorphisms (SNPs; see Table 1 for details). It is known that rs1800497 is located within the eleventh ankyrin repeat of ANKK1 gene on the opposite DNA strand (Neville et al 2004). We refer to it as DRD2 throughout the text for consistency with previous literature on its association with SUDs. The majority of meta-analyses on COMT involve associations with other psychiatric outcomes such as schizophrenia (Munafo et al. 2005) and Alzheimer’s disease (Lee and Song 2014). There is some research, however, showing an interaction between the risk allele (Val) and early cannabis use predicting subsequent psychosis (Caspi et al. 2005; Estrada et al. 2011). It is important to note that results from Genome-Wide Association Studies (GWAS), which correct for multiple testing of all available SNPs in the genome, have shown no evidence that either of two SNPs we examine here (COMT: rs4680 and DRD2: rs1800497) are significantly associated with several addiction or externalizing problems, such as nicotine and alcohol dependence (e.g., see Bierut et al 2010, Dick et al 2011, Gelernter et al 2014, Gelernter et al 2015, Loukola et al 2015, McGue et al, 2013, Vink et al 2009 and more).

In terms of the effects of the other candidate genes related to dopamine regulation, Stapleton and colleagues (2007) showed evidence of a small but significant effect of DAT1 on smoking cessation ($ORs = 1.15–1.20$). With respect to DRD2, Ohmoto and colleagues (2013) subsequently showed the effect of this gene on smoking initiation, persistence, and cessation, and that this may be specific to Caucasian males. Additional meta-analyses seem to support this conclusion (Munafo et al. 2009; Nikolaidis and Gray 2010). On the other hand, a review of 42 studies evaluated the link between DRD4 in relation to alcohol dependence and found no consistent evidence of effects (Forero et al. 2015), and similar null effects for alcohol dependence were reported for MAOA and several other candidate genes (Forero et al., 2015).

While publication bias may be at play in the meta-analyses and supporting literature for the six included candidate genes (as reviewed above, see Duncan and Keller 2011; Duncan et al. 2014), Table 1 nonetheless illustrates that a sizeable body of research supports the potential association between each candidate gene and the outcomes of interest here. Additionally, this review suggests there may be unique ethnicity and sex effects to many of these candidate genes (e.g., Ohmoto et al 2013, Byrd and Manuck 2014) which are often not accounted for in analyses of gene-environment interplay (Keller 2014).

Goals of the Current Study

In the current work, we present main effect results for the associations between these six widely studied candidate genes (MAOA, 5-HTTLPR, COMT, DRD4, DAT1, DRD2) and five early adult SUD and externalizing outcomes (nicotine dependence, alcohol use disorder, cannabis use disorder, adult antisocial behavior, and an aggregate externalizing measure using all four externalizing disorder symptom counts) across the test sample (MCTFR) and the replicate samples (MN ADHD, SSDP, RHC). All studies include highly similar phenotype and environment measures as well as ages of assessment, which are key ingredients to testing our models. Following published guidelines (Dick et al. 2015), we provide power analyses for the test sample (MCTFR) and each of the replication samples (MN ADHD, SSDP, RHC), rule out potential confounding effects of sex and ancestry, and present meta-analyzed main effects results from the independent analyses across the five studies to give population estimates of the effects. We conclude with our plan for future analyses of candidate gene-environment interplay given the findings of the main effects analyses.

Method

Participants

MCTFR (test sample)—Two studies from MCTFR, the Minnesota Twin Family Study (MTFS) and the Sibling Interaction and Behavior Study (SIBS), were combined to make up the test sample. The general purpose of both MTFS and SIBS studies was to evaluate the genetic and environmental influences on SUDs and related psychopathology in the transition from adolescence through young adulthood. These studies have similarly-aged participants with data available in young adulthood, comparable assessment batteries, and nearly identical laboratory protocols (PI's William Iacono and Matt McGue). Thus, pooling these samples for data analysis is appropriate. As each of these studies and their collaborative efforts have been described elsewhere (see Iacono et al. 1999; McGue et al. 2007), they will be only briefly reviewed here. MTFS is a community twin sample, which initially assessed Minnesota-born twins at age 11 or 17 (two separate cohorts) with follow-up assessments every 3–5 years through age 29 (assessed from 1990–2013). Over 90% of identified twin families were located and over 80% of the located, eligible families participated at baseline. Retention rates were high across follow-up assessments (range 88%–93%), and there has been limited impact of attrition on SUDs (see Iacono et al. 1999; Vrieze et al. 2014 for more detail). Consistent with state demographics from relevant birth years, the majority of the participants were of European ancestry (96%). The total MTFS sample size is 2,769

participants from 1,382 twin pairs (65% monozygotic twins, including 5 triplets, 52% female).

SIBS includes three types of families where participating offspring were biologically related or related by adoption. Participating offspring were within 5 years of age; all adoptees were placed prior to their second birthday (M age of placement is 4.7 months, $SD = 3.4$; 96% placed before their first birthday). Families were initially assessed when children were in early adolescence (M age = 14.7, $SD = 1.9$), with follow-up assessments every 3–5 years through early adulthood (at first follow-up: M age = 18.3, $SD = 2.1$; at second follow-up: M age = 22.3, $SD = 1.9$; assessed from 1998–2004). There was limited attrition over time (range 90% to 94% retention). The total eligible SIBS sample size is 1,226 participants from 613 eligible families (56% adoptive, 55% female; 53% European ancestry, 39% Asian ancestry, 1% African ancestry, 7% mixed or other ancestry; see McGue et al. 2007; Samek et al. 2014 for more detail).

For the present analyses, we excluded respondents who did not have data past age 17 from both MTFS and SIBS (in order to better assess a lifetime measure of SUD and externalizing problems in adulthood, central to the purpose of this paper and Bailey et al.'s 2011 conceptual model). The remaining 3,487 participants (2,514 MTFS, 973 SIBS; 87% of total sample) comprised the test sample (54% female; 84% European, 11% Asian ancestry, <1% African ancestry, <4% mixed or other ancestry).

MN ADHD Study (replicate sample)—The purposes of the MN ADHD and Drug Abuse Study (PI Ken C. Winters; Co-Investigators George Realmuto and Gerald August) were twofold: 1) to examine the association of candidate genes and substance use disorders and 2) to evaluate long term functioning, including SUD and related drug use behaviors, as a function of childhood externalizing diagnostic status (see August et al. 1995 for details). Three types of participants were included, those in a treatment group ($n = 443$), those in a high risk group ($n = 156$), and those in a control group ($n = 77$). The majority of the treatment group was initially recruited from various drug treatment programs in the Twin Cities metro area; 12% were recruited as an enrichment sample by virtue of having received drug treatment in the past. All participants in the treatment sample met criteria for at least one DSM-IV SUD at the time of their drug treatment.

Participants in the high risk sample were recruited from a larger, community-based sample of over 7,000 students from 22 schools around Minneapolis and St. Paul (grades 2–3) (see August et al., 1995 for details). To be included in the high risk group, participants had to score 1.75 SD or above on a teacher rating of disruptive behavior, a score of 1.75 SD above the normative mean on a parent rating of disruptive behavior and either a DSM-III-R diagnosis of attention-deficit/hyperactivity, conduct disorder, or oppositional defiant disorder. Controls were demographically matched and drawn from the same schools as those for the high-risk group. They scored less than 1 SD above the mean on the teacher rating of disruptive behavior, had no history of psychotropic medication use, and no prior school or clinic evaluation for academic or behavior problems. The majority of participants had 4–5 follow-up assessments from childhood to adolescence, roughly spaced every 2–3 years. There was limited attrition over time (participation range 72% to 80%).

The total sample size used for this study included the 621 participants with genotype data (92% of total sample; 40% female; 87% European ancestry, 6% African ancestry, 7% other or mixed ancestry).

SSDP (replicate sample)—The Seattle Social Development Project has been described previously (Hawkins et al. 1999; 2005). Briefly, the study sought to test a preventive intervention delivered in the elementary grades and to understand risk and protective factors for antisocial behavior from childhood into adulthood. The study began in 1985, and included 808 participants (77% of those eligible) in 18 participating Seattle area schools. In addition to intervention analyses, the study has permitted a broad range of etiological analyses, including the current examination of gene-environment interplay (PI, Karl G. Hill). The present study makes use of data collected annually from participants at ages 10–16, and at ages 18, 21, 24, 27, 30, 33 and 35. Sample retention was high, with over 90% of living respondents retained at each wave from ages 14–33, thus minimizing risk for bias due to attrition. About 49% of respondents were female, and the sample was ethnically/racially diverse: 47% were of European ancestry, 26% of African ancestry, 22% of Asian ancestry, and 5% of Native American ancestry; of these, 5% were Hispanic or Latino/a.

The total sample size used for this study included the 577 participants with genotyped data (74% of total sample; 54% female; 46% European ancestry, 19% African ancestry, 35% other or mixed ancestry).

RHC (replicate sample)—Raising Healthy Children began in 1992, and was intended as a replication and extension of SSDP (see Brown et al. 2005; Catalano et al 2003; Haggerty et al. 2006 for additional study details). The sample included 1,040 individuals (76% of those eligible) in first (younger cohort) or second grade (older cohort) in 10 Seattle-area suburban elementary schools. Participants were surveyed annually in the spring from ages 5–6 to 24–25, with additional fall surveys added in the two years following high school. Retention has been 85% or higher at each wave, suggesting minimal risk for bias due to attrition. About 47% of participants were female. The racial/ethnic composition of the sample was 75% European ancestry, 6% Asian ancestry, 3% African ancestry, 3% Native American ancestry, 13% Mixed ancestry; of these, 8% were Hispanic or Latino/a.

It should be noted that DNA samples were not solicited from all participants; budgetary constraints allowed collection from a maximum of 670 participants. The total sample size used for this study included the 601 participants with genotype data (58% of total sample, 90% of targeted sample; 41% female; 74% European ancestry, 3% African ancestry, 23% other or mixed ancestry).

Phenotype Measurement

MCTFR (test-sample)

Because DSM III-R was the diagnostic system in place when the study began, phenotypes included a lifetime DSM III-R symptom count for nicotine dependence, alcohol use disorder, cannabis use disorder, and adult antisocial behavior (alcohol and cannabis use disorder was assessed as the max of abuse and dependence symptoms, lifetime symptom

count was calculated by taking the max symptom count across assessments). The Substance Abuse Module of the Composite International Diagnostic Interview (Robins et al. 1988) was used to assess all SUD symptoms. The Structured Clinical Interview for DSM-III-R Axis II (Spitzer et al. 1987) was adapted to assess adult antisocial behavior symptoms (the adult criteria for adult antisocial personality disorder). All symptoms were reviewed by at least two individuals with advanced training and consensus by both individuals was necessary to assign symptoms. Kappa coefficients were $> .90$ for all SUDs and $.79$ for adult antisocial behavior. The aggregate externalizing phenotype was computed by standardizing and averaging the nicotine, alcohol, cannabis, and adult antisocial behavior lifetime symptom counts. The average age from which the young adult SUD and adult antisocial behavior phenotypes were assessed was 27.20 years ($SD = 3.5$).

MN ADHD Study (replicate sample)

Phenotypes included DSM-IV nicotine dependence, alcohol use disorder, and cannabis use disorder symptom counts (adult antisocial behavior as a component of adult antisocial personality disorder was not assessed, alcohol use disorder and cannabis use disorder were computed by taking the max across abuse and dependence symptoms). SUD symptoms were assessed using a DSM-IV structured diagnostic interview or the Adolescent Diagnostic Interview (ADI; Winters and Henly 1993). The ADI is associated with favorable inter-rater reliability and convergent validity (ADI scores with independent ratings; Winters et al. 1999). Kappa coefficients for alcohol and cannabis use disorders ranged from $.71$ to $.82$ (see Winters et al. 1993). In lieu of measurement of adult antisocial behavior, the Deviant Behavior scale was used as a measure of general externalizing problems/deviant behavior (Winters 1999). This scale includes 10 items, such as “I have been in a fight where I used a weapon,” $\alpha = .91$. The lifetime assessment of each symptom count was computed by taking a max of the symptom counts across assessments. The aggregate externalizing phenotype was computed by standardizing and averaging the nicotine, alcohol, cannabis symptom accounts and the externalizing measure.

SSDP (replicate sample)

Phenotypes included symptom counts for DSM-IV (APA 1994) alcohol and marijuana abuse/dependence and nicotine dependence as well as a crime variety count to capture antisocial behavior. Abuse and dependence symptom counts for alcohol and marijuana and dependence symptom counts for nicotine were obtained using the Diagnostic Interview Schedule (DIS; Robins et al. 1981). Only two of a possible 7 nicotine dependence symptoms were assessed at age 21 and 5 were assessed at age 24. At ages 21 and 24, marijuana use was grouped with other illicit drug use in the abuse/dependence assessments. For this paper, marijuana abuse/dependence symptom counts at ages 21 and 24 were created for those individuals who reported marijuana use but no other illicit drug use. For individuals reporting both marijuana and other illicit drug use, marijuana abuse/dependence symptom counts were treated as missing. At each wave, respondents reported whether they had engaged in a series of violent, nonviolent, and property crime behaviors in the past year. The number of different past year crimes was tallied at each age. The highest lifetime score for each of these constructs (e.g., highest alcohol abuse/dependence symptom count across ages) was used in the present analysis. An aggregate externalizing behavior measure was created

by using factor analysis of the maximum lifetime abuse/dependence and crime scores to create a factor score.

RHC (replicate sample)

Phenotypes included DSM-IV (APA 1994) symptom counts for alcohol and marijuana abuse/dependence and nicotine dependence as well as a crime variety measure. Alcohol and marijuana abuse/dependence symptom counts were assessed using the Composite International Diagnostic Interview (WHO 1990) in 2008 when the younger cohort was 21 and the older cohort was 22 and in 2011 at ages 24/25. At the age 21/22 survey, marijuana and other illicit drugs were combined in the abuse/dependence assessment. Age 21/22 marijuana symptom counts were created for those individuals who reported using only marijuana but no other illicit drugs; scores were left missing for those who used other drugs in addition to marijuana. The maximum number of alcohol and of marijuana abuse/dependence symptoms across ages 21/22 and 24/25 was used in analyses. Nicotine dependence symptoms were assessed once using the DIS in 2011 at age 24/25. A crime variety score similar to that used in SSDP was obtained each year at ages 19–24/25, and the maximum number of crimes reported in any of these years was used in analyses. As in the SSDP sample, the aggregate externalizing measure was a latent factor score obtained using confirmatory factor analysis of the maximum lifetime abuse/dependence and crime scores.

Candidate Gene Measurement and Coding

Candidate gene polymorphisms were assessed following the protocols described in Haberstick et al. (2014) and Haberstick and Smolen (2004). Candidate genes were coded as an additive function of risk alleles (0-1-2) based on previous research (Table 1). For MAOA, which is X-linked, males have 1 copy whereas females have 2. Coding of MAOA for females has been treated in multiple ways in prior research: excluding females altogether, excluding females that are heterozygous, or conducting separate analyses for females in comparison to males using separate coding systems. To combine analyses across males and females and retain maximal power, we excluded heterozygous females ($n = 470$). To confirm that this did not greatly impact results, we separately tested the MAOA-phenotype associations in the female only-test sample (MCTFR, $n = 1,462$) using the 0, 1, or 2 coding compared to the 0 versus 2 coding and found essentially identical results. Finally, we computed an aggregate genetic risk score by summing the risk alleles across the 6 candidate genes. Individuals missing more than 1 candidate gene score were coded as missing on this aggregate measure ($n = 1,537$ included for MCTFR, $n = 606$ for MN ADHD Study, and $n = 577$ for SSDP (only COMT was collected for RHC thus is not available for aggregate genetic risk score analysis)¹.

¹We checked to see whether normalizing the genetic risk score (calculated by dividing by the number of assessed risk alleles in each person) impacted results in the test sample (MCTFR). The correlation between the original genetic risk score and the normalized genetic risk score was nearly perfect ($r = .98$, $p < .001$), suggesting limited impact. We also checked whether the pattern of results changed as a result of using the normalized variable in the test sample and found essentially identical results.

Autosomal Marker Measurement

Autosomal marker data was collected using the Illumina's Human660W-Quad Array (Illumina, Inc., San Diego, CA) in the MCTFR sample. Among all eligible MCTFR participants, 77% provided a blood sample and 6% a saliva sample (more details on MCTFR sample genotyping can be found in McGue et al. 2013 and Miller et al. 2012). For the MN and ADHD Study, the Illumina HumanOmni2.5-8 Bead Chip was used (Illumina, Inc., San Diego, CA) and 91% of the sample provided via buccal swabs (saliva). For SSDP and RHC, the Illumina Omni 2.5 chip (Illumina, Inc., San Diego, CA) was used. For SSDP, 100% of the sample was ascertained saliva sample. For RHC, 93% of the 674 participants who provided DNA provided a blood sample, 7% provided a saliva sample (COMT was the only candidate gene available in the RHC sample). Across the test and replicate samples, and following the protocols described in McGue et al. (2013) and Miller et al. (2012), SNP markers were excluded under the following conditions: 1) a call rate < 99%, 2) minor allele frequency < 1%, 3) significant deviation from Hardy-Weinberg equilibrium, 4) more than two Mendelian inconsistencies across families or mismatch in duplicate samples, 5) an association with participant sex, or 6) previously identified as a bad marker on the array.

Ancestry Principal Components

Ancestry principal components were calculated using all common autosomal markers across the test and replicate samples using PLINK (version 1.90b1a). We first selected the 81,320 autosomal markers that were shared by the 9,147 subjects in the four data sets (MCTFR, MN ADHD, SSDP, RHC). We dropped one marker from every pair of markers where r^2 exceeded .30. After pruning, 61,936 markers remained. Using PLINK again, we computed realized genetic relationships on the remaining markers for all 41,829,231 pairs of subjects and identified 5,738 subjects with pairwise values of less than .2 in the genetic relationship matrix for all possible pairs of subjects. We then used R (version 3.0.1) with the rARPACK library to compute the first ten eigenvectors and eigenvalues from the relationship data for those 5,738 subjects. These eigenvectors and eigenvalues were then used to compute eigenvector values for the remaining participants by projecting from their genetic relationship values into the eigensystem determined by their relatives.

Analysis plan

We evaluated the effect of the independent variables (each of the 6 candidate genes) on each of the dependent variables (nicotine dependence, alcohol use disorder, cannabis use disorder, adult antisocial behavior, aggregate externalizing measure) after adjusting for age at most recent assessment and the first ten ancestry principal components as covariates. Our *a priori* alpha was set to .008 based on a multiple-testing correction for the number of independent candidate genes evaluated (alpha = .05 divided by six tests for the six independent candidate genes). All analyses were conducted in Mplus version 7.2 (Muthén and Muthén 1998–2012) using the maximum likelihood with robust standard errors (MLR) estimator to account for non-normality of the dependent variables. Analyses on the MCTFR sample accounted for non-independence of cases (i.e., twin/sib data) by clustering the analyses by family ID.

Prior research has shown that genetic main effects on complex phenotypes like addiction and externalizing are likely to be very small in magnitude, with most accounting for less than 1%

of phenotypic variance (see Dick et al. 2015). A power analysis was conducted in Mplus, 7.2 (Muthén and Muthén 1998–2012) to determine if we had an adequate test sample size to detect small effects ($\beta = .07$, $r^2 = 0.5\%$); power was estimated at 97% for $N = 3,000$, 60% for $N = 1,000$, 51% for $N = 800$, and 41% for $N = 600$.

Our analysis in each of the test and replicate samples followed a specific pattern. First, we analyzed results using the entire sample, and then confirmed results in those exposed to each substance (i.e., those that had ever used nicotine, alcohol, or cannabis for the analyses corresponding to nicotine dependence, alcohol use disorder and cannabis use disorder, respectively). No exposure variable was set for antisocial behavior. As the majority of the test sample is of European ancestry (~85%), and much of the prior research involving these candidate genes is on European ancestry samples alone, we also confirmed results in each of the test and replicate samples for those of European ancestry only.

We also aggregated the independent effects for each sample to provide population estimates for each effect using the Comprehensive Meta-Analysis 2.0 software (Borenstein, Hedges, Higgins, & Rothstein, 2005). Because the statistics for all independent effects for each sample were the same (standardized beta coefficients and standard errors) with the same covariates (age, the first ten ancestry principal components as covariates), we were able to calculate mean effect sizes using the beta coefficients (see Peterson & Brown, 2005). Mean effect sizes across samples were calculated by weighting each individual effect size by the inverse of its variance. A random effects model, in which both random and systematic components are assumed to account for effect size variance, was used to fit the effect size data.

Finally, exploratory analyses were subsequently conducted to evaluate potential sex differences in candidate gene-phenotype associations and to rule out any potential confounding (Keller 2014). This was done by evaluating all results in the test sample (MCTFR) separately for males and females. Significant differences were tested by constraining the candidate gene-phenotype association to be equivalent across males and females and using the chi-square difference test to evaluate for a decrement in model fit between free and constrained models. If any significant differences were found in the test-sample, follow-up analyses were conducted to test those associations in the replicate samples.

Results

Table 2 shows descriptive statistics on study phenotypes across the test and replicate samples by sex for the European ancestral group and the non-European ancestral group (including African, Asian, Hispanic, and mixed ethnic ancestry). Non-European ancestral groups were grouped together as there was not sufficient power to test for candidate gene-phenotype associations within each sub-group (see power analyses for replicate samples, above). As demonstrated in Table 2, there was adequate prevalence and variability in each of the outcomes across all studies. The highest average symptom counts were found for the MN ADHD Study, which includes both treatment and high risk samples, whereas MCTFR, SSDP, and RHC had more comparable means as they are community-based samples. In the

MCTFR and SSDP samples, males had significantly greater average SUDs than females with moderate effect sizes (Cohen's d range .26 – .61). There were few differences in those of European versus mixed ancestral groups in the MCTFR, SSDP, and RHC samples, however some moderate effects in the MN Drug Abuse and in the MN ADHD study (Cohen's d range –.37 to .00).

Table 3 shows the associations between candidate genes and phenotypes for each study. As illustrated in the MCTFR column, there were no significant associations between any of the candidate genes and phenotypic outcomes that met the threshold of $p < .008$. In fact, there were only three nominal associations that met a threshold of $p < .05$ (DAT1 and cannabis, DAT1 and cannabis for those exposed to cannabis only, and MAOA and antisocial behavior). Confirming the null findings in the test samples, no associations reached the threshold of $p < .008$ in any of the replicate samples, and the nominal associations ($p < .05$) were also not replicated. Meta-analyzed β s were generally estimated at .00 (ranged from –.03 to .03, see Table 3) and none reached statistical significant at $p < .008$ or $p < .05$.

Table 4 shows results of the associations between candidate gene and phenotypes, by study, for those of European ancestry only. In the test (MCTFR) sample, a similar pattern of null effects was found with one exception: the association between DAT1 and cannabis for those that had been exposed to cannabis was found to be significant at the *a priori* threshold ($\beta = .09$, $S.E. = .03$, $p = .006$). This effect was not replicated in any of the replicate samples (MN ADHD study: $\beta = -.03$, $S.E. = .05$, $p = .56$; SSDP: $\beta = -.04$, $S.E. = .06$, $p = .45$; not available in RHC). The meta-analyzed β for the association between DAT1 and cannabis for those exposed and of European ancestry alone = .04, $p = .07$. Altogether, and following results using the entire sample, The meta-analyzed β s for the sub-sample of those of European ancestry alone were generally estimated at .00 (ranged from –.04 to .04, see Table 4) and none reached statistical significant at $p < .008$ or $p < .05$.

Subsequently, sex differences were tested in the MCTFR sample. A detailed table showing the results for this analysis is given Supplementary Materials, eTables1. In general, few sex differences were found, although a pattern of effects was detected between DAT1 and the alcohol, cannabis, and the externalizing aggregate phenotypes by sex for p -values at the nominal level ($< .05$). Specifically, the DAT1 risk allele was positively associated with these phenotypes for males (β 's = .09, p 's ranged from .02 – .03) but not females (β 's ranged from –.01 to –.07, p 's ranged from .04 to .86). Constraining these associations to be equal across the two sexes resulted in a significant decrement to model fit (χ^2 's ranged from 4.14 to 11.97 on 1 df , p 's ranged from .007 to .04). These sex differences did not replicate in the other samples (see eTables 2–3). Similar results and non-replication were found when restricting the sample to individuals of European ancestry in the test sample (eTable 4) and the replicate samples (eTables 5–7). In short, there was no replicated evidence for sex differences in candidate gene-phenotype associations.

Discussion

This work represents an important step in an on-going collaboration among five longitudinal studies developing conceptual models of gene-environment interplay. Our goal for this

analysis was to test main effects of six candidate genes on a range of SUDs and externalizing outcomes and replicate them in multiple samples. The six candidate genes tested were selected as they are the most extensively studied candidate genes to date (in relation to SUD and externalizing problems broadly) and following this, were also available for analysis across most of our five studies (see Table 1 for an overview of each gene, function, coding, and supporting literature). After correction for multiple testing, we found one “hit” in the test sample that met the corrected for multiple testing level of significance. DAT1 was related to cannabis use disorder symptomology for those of European ancestry who had ever used cannabis. This association, however, was not replicated in pattern or significance in any of the replication data sets, and the meta-analyzed standardized regression coefficient was not significantly different from zero. Additionally, no replicated sex differences were found.

Plan and Expectations for Future Collaborative Efforts

Although we did not find candidate gene main effects, our plan is to continue on to test the general/specific conceptual model as outlined by (Bailey et al. 2011). This model posits that genetic effects interacting with general versus tobacco- and alcohol-specific family environments may differentially relate to a general latent factor of externalizing problems versus unique variance in nicotine dependence or alcohol use disorder. For example, it is possible that tobacco specific environments may exacerbate nicotine-related genetic risk, while the dopaminergic candidate genes studied here may exacerbate general environmental risk. As results did not show that any candidate gene in particular may be more relevant to a variety of externalizing disorders in the present paper, we plan to include all six candidate genes in future analysis of candidate gene x environment interaction, and include a multiple-testing correction to test for the six candidate gene tests as was done here.

Based on arguments made by Bakermans-Kranenburg and van IJzendoorn (2015), because we failed to find any main candidate gene main effects on externalizing outcomes here, we might expect to be more likely to find evidence for differential susceptibility rather than diathesis stress models of gene-environment interaction in our subsequent analyses. Differential susceptibility refers to the notion that those most at risk in adverse environments will also fare the best in optimal environments, in part because their specific genotype is more sensitive to environmental context compare to other genotypes. Alternatively, diathesis stress refers to the notion that those at genetic risk tend to do worse in more adverse environments, in parts because the stressful environment triggers their genetic risk. It has been argued that it is nearly impossible to detect a gene-environment interaction effect without a gene main effect for interactions in line with a diathesis stress framework (Risch et al. 2009), but that interactions involving differential susceptibility can and should be detected without a genetic main effect (see Bakermans-Kranenburg and van IJzendoorn 2015 for a detailed review).

In addition to testing the conceptual model of gene-environment interplay developed by Bailey and colleagues (2011), we have developed an additional model that accounts for potential gene x environment x *development* interaction (see Figure 1). This model is based on recent work both in the Minnesota lab and others (Johnson et al. 2009; Kendler et al.

2011; Samek et al. 2015; Samek et al. 2016). This model is simple extension of Bailey et al.'s (2011) original model in that it proposes an analysis of gene-environment correlation and interaction involving adolescent environmental contexts in relation to *adolescent* externalizing problems as well as young adult externalizing problems. This model also includes the adolescent peer context in addition to the adolescent family context. Testing this model will support whether gene-environment interaction involving *adolescent* environmental contexts may be developmentally limited to *adolescence*, or whether it has long-lasting effects into adulthood.

Strengths, Limitations, and Concluding Thoughts

A major strength of this study is the utility of the test-replicate approach in evaluating the effect of six widely studied candidate genes in relation to SUD and externalizing behavior outcomes. While we provided evidence for one significant effect in the test sample, it failed to replicate in the other samples. We accounted for and thoroughly analyzed potential confounders (ancestry and sex differences), presented a power analysis demonstrating power to find small effects in each of our samples, and presented a plan for future candidate gene-environment interaction analyses based on the null effects reported here. These have been argued to be essential ingredients in any future work involving candidate genes (e.g., Dick et al. 2015), and we have taken great care to follow such guidelines.

This study is of course not without its limitations. While there was diversity in sample design and participant characteristics across the five longitudinal studies, each of the included samples were still predominately of European ancestry. The five samples involved in the present study do not have sufficient power to test for these candidate-gene phenotype associations within specific racial/ethnic groups other than Caucasian. Rather than exclude ethnic minorities altogether, we dealt with this potential confounding effect by accounting for ancestry principal components in our model, and by providing results for the entire sample and then for those of European ancestry only (in order to understand if these effects may be specific to those of European ancestry alone). It would be ideal to replicate results in relatively large samples (e.g., 3,000+) of those with predominately African, Asian, Native American, and other U.S. ethnic minority ancestral groups.

In conclusion, this initial work represents an important step in an ongoing collaboration across five longitudinal studies. We did not find any replicated patterns in terms of candidate gene main effects. We presented two conceptual models of gene-environment interplay we aim to subsequently test, and offer a tentative expectation that any interaction effects we may find will be in line with a differential susceptibility rather than diathesis stress framework based on our null effects findings. We encourage others to test either of our proposed models of gene-environment interplay with similar candidate genes as well as other markers of genetic influence that may be relevant to the development of SUDs and externalizing problems.

Finally, it remains imperative to discuss the practical utility of demonstrating any gene effects given the likelihood that any effects we may find will likely be small in effect size. While theoretically relevant to understanding the dynamic interplay between individual-level variables and social context, there are other measures of individual-level risk for SUDs that

have long been demonstrated to have moderate to substantial influences on SUDs, such as personality traits including impulsivity or negative emotionality (Chassin et al. 2004; Durbin and Hicks 2014; Hicks et al. 2012; McGue et al. 1999; McGue et al. 1997; Quinn and Fromme 2011; Quinn and Harden 2013). It can be argued that such personality trait x environmental context interactions are comparatively understudied in comparison to gene x environment interactions and that personality-environment interplay may have more practical utility for SUD and externalizing prevention and treatment programs (given the relative ease and non-invasiveness of personality measurement and identification of those at risk for SUD and externalizing problems). Finally, other aspects of environmental risk not limited to the family - such as peer, school/work, and community (Hawkins et al. 1992) may be more relevant to future personality or gene-environment interaction work than family environmental risk alone. Further research should be conducted that analyzes these additional aspects of environmental risk in models of gene- or personality x environment interplay.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Funding

This research was supported by Grants DA024417, DA05147, DA13240, DA012995, DA024411-01-06, DA009679, DA036216, DA008093-15-18, and DA037280 (to S. W.) from the National Institute on Drug Abuse and Grant AA09367, and Grant AA11886 from the National Institute of Alcohol Abuse and Alcoholism. The first author (D. R. S.) was also supported by the USDA National Institute of Food and Agriculture, Hatch project 1006129. The content is solely the responsibility of the authors and does not necessarily represent the official views of the aforementioned funding agencies.

Authors Ken C. Winters and Susanne Lee would like to thank Dr.'s George Realmuto and Irv Gottesman for their help consulting with the genetic portion of their study.

References

- Anchordoquy HC, McGeary C, Liu LP, Krauter KS, Smolen A. Genotyping of three candidate genes after whole-genome preamplification of DNA collected from buccal cells. *Behavior Genetics*. 2003; 33(1):73–78. [PubMed: 12645824]
- APA. Diagnostic and Statistical Manual of Mental Disorders. 4. American Psychological Association; Washington, DC: 1994.
- August GJ, Realmuto GM, Crosby RD, MacDonald AW 3rd. Community-based multiple-gate screening of children at risk for conduct disorder. *J Abnorm Child Psychol*. 1995; 23(4):521–544. [PubMed: 7560560]
- Bailey JA, Hill KG, Meacham MC, Young SE, Hawkins JD. Strategies for characterizing complex phenotypes and environments: General and specific family environmental predictors of young adult tobacco dependence, alcohol use disorder, and co-occurring problems. *Drug and Alcohol Dependence*. 2011; 118(2–3):444–451. [PubMed: 21636226]
- Bailey JA, Samek DR, Keyes MA, Hill KG, Hicks BM, McGue M, Iacono WG, Epstein M, Catalano RF, Haggerty KP, Hawkins JD. General and substance-specific predictors of young adult nicotine dependence, alcohol use disorder, and problem behavior: replication in two samples. *Drug Alcohol Depend*. 2014;138161–168.

- Bakermans-Kranenburg MJ, van IJzendoorn MH. Differential susceptibility to rearing environment depending on dopamine-related genes: New evidence and a meta-analysis. *Development and Psychopathology*. 2011; 23(1):39–52. [PubMed: 21262038]
- Bakermans-Kranenburg MJ, van IJzendoorn MH. The Hidden Efficacy of Interventions: Gene x Environment Experiments from a Differential Susceptibility Perspective. *Annual Review of Psychology*. 2015; 66:381–409.
- Bierut LJ, Agrawal A, Bucholz KK, Doheny KF, Laurie C, Pugh E, et al. A genome-wide association study of alcohol dependence. *PNAS*. 2010; 107(11):5082–5087. [PubMed: 20202923]
- Borenstein, M.; Hedges, L.; Higgins, J.; Rothstein, H. *Comprehensive Meta-Analysis version 2*. Englewood, NJ: Biostat; 2005.
- Bronfenbrenner U, Ceci SJ. Nature-nurture reconceptualized in developmental perspective: a bioecological model. *Psychol Rev*. 1994; 101(4):568–586. [PubMed: 7984707]
- Brookes K, Xu X, Chen W, Zhou K, Neale B, Lowe N, Anney R, Franke B, Gill M, Ebstein R, Buitelaar J, Sham P, Campbell D, Knight J, Andreou P, Altink M, Arnold R, Boer F, Buschgens C, Butler L, Christiansen H, Feldman L, Fleischman K, Fliers E, Howe-Forbes R, Goldfarb A, Heise A, Gabriels I, Korn-Lubetzki I, Johansson L, Marco R, Medad S, Minderaa R, Mulas F, Muller U, Mulligan A, Rabin K, Rommelse N, Sethna V, Soroohan J, Uebel H, Psychogiou L, Weeks A, Barrett R, Craig I, Banaschewski T, Sonuga-Barke EJS, Eisenberg J, Kuntsi J, Manor I, McGuffin P, Miranda A, Oades DR, Plomin R, Roeyers H, Rothenberger A, Sergeant J, Steinhausen HC, Taylor E, Thompson M, Faraone SV, Asherson P. The analysis of 51 genes in DSM-IV combined type attention deficit hyperactivity disorder: association signals in DRD4, DAT1 and 16 other genes (vol 11, pg 934, 2006). *Molecular Psychiatry*. 2006; 11(12):1139–1139.
- Catalano RF, Mazza JJ, Harachi TW, Abbott RD, Haggerty KP, Fleming CB. Raising healthy children through enhancing social development in elementary school: Results after 1.5 years. *Journal of School Psychology*. 2003; 41:143–164.
- Brown EC, Catalano RF, Fleming CB, Haggerty KP, Abbott RD. Adolescent substance use outcomes in the Raising Healthy Children project: A two-part latent growth curve analysis. *Journal of Consulting and Clinical Psychology*. 2005; 73(4):699–710. [PubMed: 16173857]
- Byrd AL, Manuck SB. MAOA, childhood maltreatment, and antisocial behavior: meta-analysis of a gene-environment interaction. *Biol Psychiatry*. 2014; 75(1):9–17. [PubMed: 23786983]
- Caspi A, McClay J, Moffitt TE, Mill J, Martin J, Craig IW, Taylor A, Poulton R. Role of genotype in the cycle of violence in maltreated children. *Science*. 2002; 297(5582):851–854. [PubMed: 12161658]
- Caspi A, Moffitt TE, Cannon M, McClay J, Murray R, Harrington H, Taylor A, Arseneault L, Williams B, Braithwaite A, Poulton R, Craig IW. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: Longitudinal evidence of a gene X environment interaction. *Biological Psychiatry*. 2005; 57(10): 1117–1127. [PubMed: 15866551]
- Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, McClay J, Mill J, Martin J, Braithwaite A, Poulton R. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. *Science*. 2003; 301(5631):386–389. [PubMed: 12869766]
- Census. Minnesota, Population by Race: Race and Ethnicity Selections, 1980–2000. 2000.
- Chabris CF, Hebert BM, Benjamin DJ, Beauchamp J, Cesarini D, van der Loos M, Johannesson M, Magnusson PK, Lichtenstein P, Atwood CS, Freese J, Hauser TS, Hauser RM, Christakis N, Laibson D. Most reported genetic associations with general intelligence are probably false positives. *Psychol Sci*. 2012; 23(11):1314–1323. [PubMed: 23012269]
- Chassin L, Forth DB, King KM. Trajectories of alcohol and drug use and dependence from adolescence to adulthood: the effects of familial alcoholism and personality. *J Abnorm Psychol*. 2004; 113(4): 483–498. [PubMed: 15535782]
- Dick DM, Aliev F, Krueger RF, Edwards A, Agrawal A, Lynskey M, et al. Genome-wide association study of conduct disorder symptomatology. *Molecular Psychiatry*. 2011; 16:800–808. [PubMed: 20585324]

- Dick DM, Agrawal A, Keller MC, Adkins A, Aliev F, Monroe S, Hewitt JK, Kendler KS, Sher KJ. Candidate gene-environment interaction research: reflections and recommendations. *Perspect Psychol Sci.* 2015; 10(1):37–59. [PubMed: 25620996]
- Don RH, Cox PT, Wainwright BJ, Baker K, Mattlick JS. “Touchdown” PCR to circumvent spurious priming during gene amplification. *Nucl Acids Res.* 1992:194008.
- Duncan LE, Keller MC. A critical review of the first 10 years of candidate gene-by-environment interaction research in psychiatry. *Am J Psychiatry.* 2011; 168(10):1041–1049. [PubMed: 21890791]
- Duncan LE, Pollastri AR, Smoller JW. Mind the gap: why many geneticists and psychological scientists have discrepant views about gene-environment interaction (GxE) research. *Am Psychol.* 2014; 69(3):249–268. [PubMed: 24750075]
- Durbin CE, Hicks BM. Personality and Psychopathology: A Stagnant Field in Need of Development. *Eur J Pers.* 2014; 28(4):362–386. [PubMed: 25544802]
- Epstein M, Hill KG, Bailey JA, Hawkins JD. The effect of general and drug-specific family environments on comorbid and drug-specific problem behavior: a longitudinal examination. *Dev Psychol.* 2013; 49(6):1151–1164. [PubMed: 22799586]
- Estrada G, Fatjo-Vilas M, Munoz MJ, Pulido G, Minano MJ, Toledo E, Illa JM, Martin M, Miralles ML, Miret S, Campanera S, Bernabeu C, Navarro ME, Fananas L. Cannabis use and age at onset of psychosis: further evidence of interaction with COMT Val158Met polymorphism. *Acta Psychiatrica Scandinavica.* 2011; 123(6):485–492. [PubMed: 21231925]
- Faraone SV, Doyle AE, Mick E, Biederman J. Meta-analysis of the association between the 7-repeat allele of the dopamine D-4 receptor gene and attention deficit hyperactivity disorder. *American Journal of Psychiatry.* 2001; 158(7):1052–1057. [PubMed: 11431226]
- Feinn R, Nellissery M, Kranzler HR. Meta-analysis of the association of a functional serotonin transporter promoter polymorphism with alcohol dependence. *American Journal of Medical Genetics Part B-Neuropsychiatric Genetics.* 2005; 133b(1):79–84.
- Ficks CA, Waldman ID. Candidate genes for aggression and antisocial behavior: a meta-analysis of association studies of the 5HTTLPR and MAOA-uVNTR. *Behav Genet.* 2014; 44(5):427–444. [PubMed: 24902785]
- Forero DA, Lopez-Leon S, Shin HD, Park BL, Kim DJ. Meta-analysis of six genes (BDNF, DRD1, DRD3, DRD4, GRIN2B and MAOA) involved in neuroplasticity and the risk for alcohol dependence. *Drug Alcohol Depend.* 2015; 149:259–263. [PubMed: 25660313]
- Gelernter J, Cubells JF, Kidd JR, Pakstis AJ, Kidd KK. Population studies of polymorphisms of the serotonin transporter protein gene. *American Journal of Medical Genetics.* 1999; 88(1):61–66. [PubMed: 10050969]
- Gelernter J, Kranzler HR, Sherva R, Almasy L, Herman AI, Koesterer R, Zhao H, Farrer LA. Genome-wide association study of nicotine dependence in American populations: Identification of novel risk loci in both African-Americans and European-Americans. *Biol Psychiatry.* 2015; 77(5):493–503. [PubMed: 25555482]
- Gelernter J, Kranzler HR, Sherva R, Almasy L, Koesterer R, Smith AH, et al. Genome-wide association study of alcohol dependence: Significant findings in African and European-Americans including novel risk loci. *Molecular Psychiatry.* 2014; 19:41–49. [PubMed: 24166409]
- Haberstick BC, Lessem JM, Hopfer CJ, Smolen A, Ehringer MA, Timberlake D, Hewitt JK. Monoamine oxidase A (MAOA) and antisocial behaviors in the presence of childhood and adolescent maltreatment. *American Journal of Medical Genetics Part B-Neuropsychiatric Genetics.* 2005; 135b(1):59–64.
- Haberstick BC, Smolen A. Genotyping of three single nucleotide polymorphisms following whole genome preamplification of DNA collected from buccal cells. *Behav Genet.* 2004; 34(5):541–547. [PubMed: 15319577]
- Haberstick BC, Smolen A, Stetler GL, Tabor JW, Roy T, Casey R, ... Harris KM, et al. Simple sequence repeats in the National Longitudinal Study of Adolescent Health: An ethnically diverse resource for genetic analysis of health and behavior. *Behav Genet.* 2014; 44:487–497. [PubMed: 24890516]

- Haggerty KP, Fleming CB, Catalano RF, Harachi TW, Abbott RD. Raising healthy children: Examining the impact of promoting healthy driving behavior within a social development intervention. *Prevention Science*. 2006; 7(3):257–267. [PubMed: 16752099]
- Hawkins JD, Catalano RF, Kosterman R, Abbott R, Hill KG. Preventing adolescent health-risk behaviors by strengthening protection during childhood. *Arch Pediatr Adolesc Med*. 1999; 153(3): 226–234. [PubMed: 10086398]
- Hawkins JD, Catalano RF, Miller JY. Risk and protective factors for alcohol and other drug problems in adolescence and early adulthood: implications for substance abuse prevention. *Psychol Bull*. 1992; 112(1):64–105. [PubMed: 1529040]
- Hawkins JD, Kosterman R, Catalano RF, Hill KG, Abbott RD. Promoting positive adult functioning through social development intervention in childhood - Long-term effects from the Seattle Social Development Project. *Archives of Pediatrics & Adolescent Medicine*. 2005; 159(1):25–31. [PubMed: 15630054]
- Hawkins, JD.; SMith, BH.; Hill, KG.; Kosterman, R.; Catalano, RF.; Abbott, RD. Understanding and preventing crime and violence: Findings from the Seattle SOcial Development Project. In: Thornberry, TP.; Krohn, MD., editors. *Taking Stock of Juvenile Delinquency: An Overview of Findings from Contemporary Longitudinal Studies*. Kluwer Academic/Plenum; New York: 2003. p. 255-312.
- Hewitt JK. Editorial Policy on Candidate Gene Association and Candidate Gene-by-Environment Interaction Studies of Complex Traits. *Behavior Genetics*. 2012; 42(1):1–2. [PubMed: 21928046]
- Hicks BM, Durbin CE, Blonigen DM, Iacono WG, McGue M. Relationship between personality change and the onset and course of alcohol dependence in young adulthood. *Addiction*. 2012; 107(3):540–548. [PubMed: 21851441]
- Hill KG, Hawkins JD, Bailey JA, Catalano RF, Abbott RD, Shapiro VB. Person-environment interaction in the prediction of alcohol abuse and alcohol dependence in adulthood. *Drug Alcohol Depend*. 2010; 110(1–2):62–69. [PubMed: 20299164]
- Hung CF, Lung FW, Hung TH, Chong MY, Wu CK, Wen JK, Lin PY. Monoamine oxidase A gene polymorphism and suicide: An association study and meta-analysis. *Journal of Affective Disorders*. 2012; 136(3):643–649. [PubMed: 22041522]
- Iacono WG, Carlson SR, Taylor J, Elkins IJ, McGue M. Behavioral disinhibition and the development of substance-use disorders: findings from the Minnesota Twin Family Study. *Dev Psychopathol*. 1999; 11(4):869–900. [PubMed: 10624730]
- Johnson W, McGue M, Iacono WG. School performance and genetic and environmental variance in antisocial behavior at the transition from adolescence to adulthood. *Dev Psychol*. 2009; 45(4):973–987. [PubMed: 19586174]
- Johnston C, Lahey BB, Matthys W. Editorial Policy for Candidate Gene Studies. *Journal of Abnormal Child Psychology*. 2013; 41(4):511–514.
- Jonas KG, Markon KE. A Meta-Analytic Evaluation of the Endophenotype Hypothesis: Effects of Measurement Paradigm in the Psychiatric Genetics of Impulsivity. *Journal of Abnormal Psychology*. 2014; 123(3):660–675. [PubMed: 24978691]
- Karg K, Burmeister M, Shedden K, Sen S. The serotonin transporter promoter variant (5-HTTLPR), stress, and depression meta-analysis revisited: evidence of genetic moderation. *Arch Gen Psychiatry*. 2011; 68(5):444–454. [PubMed: 21199959]
- Keller MC. Gene x environment interaction studies have not properly controlled for potential confounders: the problem and the (simple) solution. *Biol Psychiatry*. 2014; 75(1):18–24. [PubMed: 24135711]
- Kendler KS, Gardner C, Dick DM. Predicting alcohol consumption in adolescence from alcohol-specific and general externalizing genetic risk factors, key environmental exposures and their interaction. *Psychol Med*. 2011; 41(7):1507–1516. [PubMed: 20942993]
- Kim-Cohen J, Caspi A, Taylor A, Williams B, Newcombe R, Craig IW, Moffitt TE. MAOA, maltreatment, and gene-environment interaction predicting children's mental health: new evidence and a meta-analysis. *Mol Psychiatry*. 2006; 11(10):903–913. [PubMed: 16801953]
- Kluger AN, Siegfried Z, Ebstein RP. A meta-analysis of the association between DRD4 polymorphism and novelty seeking. *Molecular Psychiatry*. 2002; 7(7):712–717. [PubMed: 12192615]

- Lee YH, Song GG. COMT Val158Met and PPAR gamma Pro12Ala polymorphisms and susceptibility to Alzheimer's disease: a meta-analysis. *Neurological Sciences*. 2014; 35(5):643–651. [PubMed: 24477323]
- Lerman C, Caporaso N, Main D, Audrain J, Boyd NR, Bowman ED, Shields PG. Depression and self-medication with nicotine: the modifying influence of the dopamine D4 receptor gene. *Health Psychol*. 1998; 17(1):56–62. [PubMed: 9459071]
- Lesch KP. Editorial: Illuminating the dark matter of developmental neuropsychiatric genetics - strategic focus for future research in child psychology and psychiatry. *J Child Psychol Psychiatry*. 2014; 55(3):201–203. [PubMed: 24552481]
- Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, Benjamin J, Muller CR, Hamer DH, Murphy DL. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. *Science*. 1996; 274(5292):1527–1531. [PubMed: 8929413]
- Li DW, Sham PC, Owen MJ, He L. Meta-analysis shows significant association between dopamine system genes and attention deficit hyperactivity disorder (ADHD). *Human Molecular Genetics*. 2006; 15(14):2276–2284. [PubMed: 16774975]
- Livak KJ. Allelic discrimination using fluorogenic probes and the 5' nuclease assay. *Genetic Analysis: Biomolecular Engineering*. 1999:14143–149.
- Lopez LS, Croes EA, Sayed-Tabatabaei FA, Claes S, Van Broeckhoven C, van Duijn CM. The dopamine D4 receptor gene 48-base-pair-repeat polymorphism and mood disorders: A meta-analysis. *Biological Psychiatry*. 2005; 57(9):999–1003. [PubMed: 15860340]
- Loukola A, Buchwald J, Gupta R, Palviainen T, Hallfors J, Tikkanen E, et al. A Genome-Wide Association study of a biomarker of nicotine metabolism. *PLOS Genet*. 2015; 11(9):e1005498. [PubMed: 26407342]
- Maher BS, Marazita ML, Ferrell RE, Vanyukov MM. Dopamine system genes and attention deficit hyperactivity disorder: a meta-analysis. *Psychiatric Genetics*. 2002; 12(4):207–215. [PubMed: 12454525]
- Mattay VS, Goldberg TE, Fera F, Hariri AR, Tessitore A, Egan MF, Kolachana B, Callicott JH, Weinberger DR. Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. *Proc Natl Acad Sci U S A*. 2003; 100(10):6186–6191. [PubMed: 12716966]
- McGue M, Keyes M, Sharma A, Elkins I, Legrand L, Johnson W, Iacono WG. The environments of adopted and non-adopted youth: evidence on range restriction from the Sibling Interaction and Behavior Study (SIBS). *Behav Genet*. 2007; 37(3):449–462. [PubMed: 17279339]
- McGue M, Slutske W, Iacono WG. Personality and substance use disorders: II. Alcoholism versus drug use disorders. *J Consult Clin Psychol*. 1999; 67(3):394–404. [PubMed: 10369060]
- McGue M, Slutske W, Taylor J, Iacono WG. Personality and substance use disorders: I. Effects of gender and alcoholism subtype. *Alcohol Clin Exp Res*. 1997; 21(3):513–520. [PubMed: 9161612]
- McGue M, Zhang Y, Miller MB, Basu S, Vrieze S, Hicks B, Malone S, Oetting WS, Iacono WG. A genome-wide association study of behavioral disinhibition. *Behav Genet*. 2013; 43(5):363–373. [PubMed: 23942779]
- Miller MB, Basu S, Cunningham J, Eskin E, Malone SM, Oetting WS, Schork N, Sul JH, Iacono WG, McGue M. The Minnesota Center for Twin and Family Research genome-wide association study. *Twin Res Hum Genet*. 2012; 15(6):767–774. [PubMed: 23363460]
- Miller R, Wankerl M, Stalder T, Kirschbaum C, Alexander N. The serotonin transporter gene-linked polymorphic region (5-HTTLPR) and cortisol stress reactivity: a meta-analysis. *Mol Psychiatry*. 2013; 18(9):1018–1024. [PubMed: 22945032]
- Monroe SM, Simons AD. Diathesis-stress theories in the context of life stress research: implications for the depressive disorders. *Psychol Bull*. 1991; 110(3):406–425. [PubMed: 1758917]
- Munafo MR, Bowes L, Clark TG, Flint J. Lack of association of the COMT (Val(158/108) Met) gene and schizophrenia: A meta-analysis of case-control studies. *Molecular Psychiatry*. 2005; 10(8):765–770. [PubMed: 15824744]
- Munafo MR, Durrant C, Lewis G, Flint J. Gene x Environment Interactions at the Serotonin Transporter Locus. *Biological Psychiatry*. 2009; 65(3):211–219. [PubMed: 18691701]

- Munafo MR, Gage SH. Improving the reliability and reporting of genetic association studies. *Drug Alcohol Depend.* 2013; 132(3):411–413. [PubMed: 23628164]
- Munafo MR, Timpson NJ, David SP, Ebrahim S, Lawlor DA. Association of the DRD2 gene Taq1A polymorphism and smoking behavior: a meta-analysis and new data. *Nicotine Tob Res.* 2009; 11(1):64–76. [PubMed: 19246443]
- Munafo MR, Yalcin B, Willis-Owen SA, Flint J. Association of the dopamine D4 receptor (DRD4) gene and approach-related personality traits: meta-analysis and new data. *Biol Psychiatry.* 2008; 63(2):197–206. [PubMed: 17574217]
- Murphy SE, Norbury R, Godlewska BR, Cowen PJ, Mannie ZM, Harmer CJ, Munafo MR. The effect of the serotonin transporter polymorphism (5-HTTLPR) on amygdala function: a meta-analysis. *Mol Psychiatry.* 2013; 18(4):512–520. [PubMed: 22488255]
- Muthén, L.K.; Muthén, B.O. *Mplus User's Guide*. 7. Muthén and Muthén; Los Angeles, CA: 1998–2012.
- Neville MJ, Johnstone EC, Walton RT. Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. *Hum Mutat.* 2004; 23:540–545. [PubMed: 15146457]
- Nikolaidis A, Gray JR. ADHD and the DRD4 exon III 7-repeat polymorphism: an international meta-analysis. *Soc Cogn Affect Neurosci.* 2010; 5(2–3):188–193. [PubMed: 20019071]
- Ohmoto M, Sakaishi K, Hama A, Morita A, Nomura M, Mitsumoto Y. Association between dopamine receptor 2 Taq1A polymorphisms and smoking behavior with an influence of ethnicity: a systematic review and meta-analysis update. *Nicotine Tob Res.* 2013; 15(3):633–642. [PubMed: 22990224]
- Peterson PA, Brown SP. On the use of beta coefficients in meta-analysis. *Journal of Applied Psychology.* 2005; 90(1):175–181. [PubMed: 15641898]
- Quinn PD, Fromme K. The role of person-environment interactions in increased alcohol use in the transition to college. *Addiction.* 2011; 106(6):1104–1113. [PubMed: 21338432]
- Quinn PD, Harden KP. Differential changes in impulsivity and sensation seeking and the escalation of substance use from adolescence to early adulthood. *Dev Psychopathol.* 2013; 25(1):223–239. [PubMed: 22824055]
- Reif A, Richter J, Straube B, Hofler M, Lueken U, Gloster AT, Weber H, Domschke K, Fehm L, Strohle A, Jansen A, Gerlach A, Pyka M, Reinhardt I, Konrad C, Wittmann A, Pfeleiderer B, Alpers GW, Pauli P, Lang T, Arolt V, Wittchen HU, Hamm A, Kircher T, Deckert J. MAOA and mechanisms of panic disorder revisited: from bench to molecular psychotherapy. *Mol Psychiatry.* 2014; 19(1):122–128. [PubMed: 23319006]
- Reif A, Weber H, Domschke K, Klauke B, Baumann C, Jacob CP, Strohle A, Gerlach AL, Alpers GW, Pauli P, Hamm A, Kircher T, Arolt V, Wittchen HU, Binder EB, Erhardt A, Deckert J. Meta-analysis argues for a female-specific role of MAOA-uVNTR in panic disorder in four European populations. *American Journal of Medical Genetics Part B-Neuropsychiatric Genetics.* 2012; 159b(7):786–793.
- Risch N, Herrell R, Lehner T, Liang KY, Eaves L, Hoh J, Griem A, Kovacs M, Ott J, Merikangas KR. Interaction between the serotonin transporter gene (5-HTTLPR), stressful life events, and risk of depression: a meta-analysis. *JAMA.* 2009; 301(23):2462–2471. [PubMed: 19531786]
- Robins, LN.; Helzer, JE.; Croughan, J.; Williams, JBW.; Spitzer, RL. *NIMH Diagnostic Interview Schedule: Version III*. National Institute of Mental Health; Rockville, MD: 1981.
- Robins LN, Wing J, Wittchen HU, Helzer JE, Babor TF, Burke J, Farmer A, Jablenski A, Pickens R, Regier DA, et al. The Composite International Diagnostic Interview. An epidemiologic instrument suitable for use in conjunction with different diagnostic systems and in different cultures. *Arch Gen Psychiatry.* 1988; 45(12):1069–1077. [PubMed: 2848472]
- Rutter M. Response to commentaries on discussion paper Gene-environment interdependence. *European Journal of Developmental Psychology.* 2012; 9(4):426–431.
- Sabol SZ, Hu S, Hamer D. A functional polymorphism in the monoamine oxidase A gene promoter. *Human Genetics.* 1998; 103(3):273–279. [PubMed: 9799080]

- Samek DR, Hicks BM, Keyes MA, Bailey J, McGue M, Iacono WG. Gene-environment interplay between parent-child relationship problems and externalizing disorders in adolescence and young adulthood. *Psychol Med*. 2015; 45(2):333–344. [PubMed: 25066478]
- Samek DR, Hicks BM, Keyes MA, McGue M, Iacono WG. Antisocial peer affiliation and externalizing disorders: Evidence for gene x environment x development interaction. *Development and Psychopathology*. 2016:1–18. online first publication.
- Samek DR, Keyes MA, Hicks BM, Bailey J, McGue M, Iacono WG. General and specific predictors of nicotine and alcohol dependence in early adulthood: genetic and environmental influences. *J Stud Alcohol Drugs*. 2014; 75(4):623–634. [PubMed: 24988261]
- Sameroff AJ, Mackenzie MJ. Research strategies for capturing transactional models of development: the limits of the possible. *Dev Psychopathol*. 2003; 15(3):613–640. [PubMed: 14582934]
- Spitzer, RL.; Williams, JBW.; Gibbon, M. Structured Clinical Interview for DSM-III-R (SCID). New York State Psychiatric Institute, Biometrics Research; New York: 1987.
- Stapleton JA, Sutherland G, O’Gara C. Association between dopamine transporter genotypes and smoking cessation: a meta-analysis. *Addict Biol*. 2007; 12(2):221–226. [PubMed: 17508996]
- Taylor A, Kim-Cohen J. Meta-analysis of gene-environment interactions in developmental psychopathology. *Dev Psychopathol*. 2007; 19(4):1029–1037. [PubMed: 17931432]
- Taylor S. Molecular genetics of obsessive-compulsive disorder: a comprehensive meta-analysis of genetic association studies. *Mol Psychiatry*. 2013; 18(7):799–805. [PubMed: 22665263]
- Vandenbergh DJ, Persico AM, Hawkins AL, Griffin CA, Li X, Jabs EW, Uhl GR. Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR. *Genomics*. 1992; 14(4):1104–1106. [PubMed: 1478653]
- Vink JM, Smit AB, de Geus EJC, Sullivan P, Willemsen G, Hottenga J, et al. Genome-wide association study of smoking initiation and current smoking. *Am J Hum Genet*. 2009; 84(3):367–379. [PubMed: 19268276]
- Vrieze SI, Vaidyanathan U, Hicks BM, Iacono WG, McGue M. The role of constraint in the development of nicotine, marijuana, and alcohol dependence in young adulthood. *Behav Genet*. 2014; 44(1):14–24. [PubMed: 24343204]
- WHO. Composite International Diagnostic Interview, Version 1.0. World Health Organization; Geneva: 1990.
- Winters KC. A new multiscale measure of adult substance abuse. *J Subst Abuse Treat*. 1999; 16(3): 237–246. [PubMed: 10194741]
- Winters, KC. Minnesota Drug Abuse and ADHD Study. Department of Psychiatry, University of Minnesota; Minneapolis, MN: 2015.
- Winters, KC.; Henly, GA. Adolescent Diagnostic Interview Schedule and Manual. Western Psychological Services; Los Angeles: 1993.
- Winters KC, Latimer W, Stinchfield RD. The DSM-IV criteria for adolescent alcohol and cannabis use disorders. *J Stud Alcohol*. 1999; 60(3):337–344. [PubMed: 10371261]
- Winters KC, Stinchfield RD, Fulkerson J, Henly GA. Measuring alcohol and cannabis use disorders in an adolescent clinical sample. *Psychology of Addictive Behaviors*. 1993; 7(3):185–196.
- Wu J, Xiao H, Sun H, Zou L, Zhu LQ. Role of dopamine receptors in ADHD: a systematic meta-analysis. *Mol Neurobiol*. 2012; 45(3):605–620. [PubMed: 22610946]
- Yang B, Chan RC, Jing J, Li T, Sham P, Chen RY. A meta-analysis of association studies between the 10-repeat allele of a VNTR polymorphism in the 3’-UTR of dopamine transporter gene and attention deficit hyperactivity disorder. *Am J Med Genet B Neuropsychiatr Genet*. 2007; 144B(4):541–550. [PubMed: 17440978]
- Zhang L, Hu L, Li X, Zhang J, Chen B. The DRD2 rs1800497 polymorphism increase the risk of mood disorder: evidence from an update meta-analysis. *J Affect Disord*. 2014:15871–77.
- Zou YF, Wang F, Feng XL, Li WF, Tian YH, Tao JH, Pan FM, Huang F. Association of DRD2 gene polymorphisms with mood disorders: a meta-analysis. *J Affect Disord*. 2012; 136(3):229–237. [PubMed: 21130502]

Figure 1. Additional (newly developed) conceptual model developed to test candidate gene x environment x development interaction

AUD = Alcohol use disorder, ND = nicotine dependence, IDUD = illicit drug use disorder, AAB = adult antisocial behavior. Circles represent latent factors, squares represent observed variables. Indicators of adolescent parent-child relationship (e.g., parent-child conflict, management, bonding, involvement) and adolescent antisocial peer affiliation (e.g., antisocial peers, prosocial peers, substance using peers) are not shown for clarity of presentation; these adolescent environmental latent factors will be indicated by 3+ scales or may be measured as observed variables depending on what data is available across the five longitudinal studies. The model proposes an analysis of candidate genes as correlates of adolescent parent-child relationship quality and antisocial peer affiliation variables and moderators of the associations between adolescent parent-child relationship quality and antisocial peer affiliation in relation a latent factor of externalizing disorders in both adolescence and young adulthood. Polygenetic risk scores or other genetic variants could be easily included in the model instead of candidate genes. *Note*, sex, age, and the first 10 principal components of ancestry will be included as covariates but are not shown in the figure for clarity of presentation.

Table 1

Overview of Included Candidate Genes

Candidate Gene	Function	Coding	Research examples
Monoamine Oxidase A (MAOA)	Deaminates several neurotransmitters, including norepinephrine, epinephrine, serotonin, dopamine	VNTR: shorter allele/fewer repeats is risk; 2-3R = S/risk; 3.5-5=L; X-linked	Meta-analyses: Byrd and Manuck 2014; Ficks and Waldman 2014; Forero et al. 2015; Hung et al. 2012; Kim-Cohen et al. 2006; Reif et al. 2012; Taylor and Kim-Cohen 2007
Serotonin Transporter Linked Polymorphic region (5-HTTLPR)	Regulates expression of serotonin transporter	VNTR: shorter allele is risk; 14 repeat = S/risk; 16 repeat=L	Meta-analyses: Feinn et al. 2005; Ficks and Waldman 2014; Jonas and Markon 2014; Karg et al. 2011; Miller et al. 2013; Murphy et al. 2013; Risch et al. 2009
Catechol-O-Methyltransferase (COMT)	Degrades catecholamines including dopamine, epinephrine, norepinephrine	SNP: A (Met) or G (Val), G (Val/Val) allele is risk	Meta-analyses: Lee and Song 2014; Munafò et al. 2005; Taylor 2013
Dopamine D4 Receptor (DRD4)	Encodes D4 subtype of dopamine receptor; activated by dopamine	VNTR: longer allele is risk; 7+ repeats = risk/L; <7R = S	Meta-analyses: Bakermans-Kranenburg and van Ijzendoorn 2011; Brookes et al. 2006; Faraone et al. 2001; Forero et al. 2015; Jonas and Markon 2014; Kluger et al. 2002; Lopez et al. 2005; Maher et al. 2002; Munafò et al. 2008; Nikolaidis and Gray 2010; Wu et al. 2012
Dopamine Transporter Gene (DAT1)	Transports dopamine out of the synapse	VNTR: shorter allele is risk; 10+repeats=L; <10 repeats=S/risk	Meta-analyses: Brookes et al. 2006; Jonas and Markon 2014; Li et al. 2006; Maher et al. 2002; Stapleton et al. 2007; Yang et al. 2007
Dopamine D2 Receptor (DRD2)	Encodes D2 subtype of the dopamine receptor; activated by dopamine	SNP, A1 or A2; A1 allele is risk	Meta-analyses: Bakermans-Kranenburg and van Ijzendoorn 2011; Lopez et al. 2005; Munafò et al. 2009; Ohmoto et al. 2013; Zhang et al. 2014; Zou et al. 2012

Notes. VNTR = Variable Number of Tandem Repeats, SNP = Single Nucleotide Polymorphism. This table overviews the six candidate genes included in our analysis, including the function, the coding, and prior research linking candidate gene main or interaction effects to substance use or externalizing problems broadly. The literature review is not meant to be all-inclusive; the included citations highlight the more recent meta-analyses when available and the nature and extent of the study of these candidate genes. Key findings of specific studies are discussed in the text.

Table 2

Means and Standard Deviations for Study Phenotypes across Sex and Ancestry by Study

	<i>M (SD)</i>					Cohen's <i>d</i>	Non-European Ancestry	Non-European Ancestry	Cohen's <i>d</i>
	Males	Females	Cohen's <i>d</i>	European Ancestry	European Ancestry				
MCTFR	(<i>n</i> = 1,618)	(<i>n</i> = 1,869)		(<i>n</i> = 2,964)	(<i>n</i> = 523)				
Nicotine dependence symptoms	1.96 (2.28)	1.39 (2.10)	.26*	1.70 (2.22)	1.42 (2.10)				.13*
Alcohol use disorder symptoms	2.51 (2.50)	1.15 (1.96)	.61*	1.83 (2.34)	1.48 (2.25)				.15*
Cannabis use disorder symptoms	1.52 (2.59)	.65 (1.70)	.40*	1.03 (2.16)	1.19 (2.41)				-.07
Adult antisocial behavior symptoms	1.91 (1.48)	1.10 (1.17)	.61*	1.49 (1.36)	1.44 (1.50)				.03
Aggregate Externalizing Phenotype	.36 (.90)	-.11 (.70)	.58*	.12 (.82)	.05 (.87)				.08
MN Drug Abuse and ADHD Study	(<i>n</i> = 364)	(<i>n</i> = 246)		(<i>n</i> = 521)	(<i>n</i> = 84)				
Nicotine dependence symptoms	3.18 (2.40)	3.41 (2.61)	-.09	3.18 (2.51)	3.79 (2.35)				-.26*
Alcohol use disorder symptoms	5.32 (3.63)	5.21 (3.82)	.03	5.22 (3.73)	5.51 (3.60)				-.08
Cannabis use disorder symptoms	5.13 (4.19)	3.95 (4.00)	.29*	4.65 (4.18)	4.65 (3.99)				0
Deviant Behavior Scale ^a	10.80 (2.14)	10.91 (2.30)	-.05	10.70 (1.92)	11.73 (3.41)				-.37*
Aggregate Externalizing Phenotype	.02 (.71)	-.02 (.71)	.06	-.03 (.70)	.17 (.76)				-.27*
SSDP	(<i>n</i> = 267)	(<i>n</i> = 310)		(<i>n</i> = 302)	(<i>n</i> = 275)				
Nicotine dependence symptoms	1.72 (1.69)	1.17 (1.60)	.33*	1.54 (1.66)	1.43 (1.75)				.06
Alcohol use disorder symptoms	2.71 (2.59)	1.68 (2.16)	.43*	2.21 (2.37)	2.11 (2.48)				.04
Cannabis use disorder symptoms	1.37 (2.32)	.68 (1.76)	.34*	.92 (1.98)	1.09 (2.16)				.08
Adult antisocial behavior symptoms	-	-	-	-	-				-
Aggregate Externalizing Phenotype	.32 (1.11)	-.25 (.85)	.58*	-.002 (.98)	.03 (1.06)				.03
RHC	(<i>n</i> = 354)	(<i>n</i> = 247)		(<i>n</i> = 443)	(<i>n</i> = 140)				
Nicotine dependence symptoms	.96 (1.52)	1.13 (1.64)	-.11	1.04 (1.59)	1.08 (1.57)				-.03
Alcohol use disorder symptoms	2.03 (2.36)	1.94 (2.41)	.04	1.99 (2.36)	2.13 (2.51)				-.06
Cannabis use disorder symptoms	1.18 (1.95)	.95 (1.97)	.12	1.13 (2.01)	.99 (1.85)				.07
Adult antisocial behavior symptoms	-	-	-	-	-				-
Aggregate Externalizing Phenotype	.03 (.98)	-.05 (1.02)	.08	.01 (1.01)	.04 (.99)				-.03

Notes: MCTFR = Minnesota Twin and Family Study, MN = Minnesota, ADHD = Attention Deficit Hyperactivity Disorder, SSDP = Seattle Social Development Project, RHC = Raising Health Children. This table shows means (*M*) and standard deviations (*SD*) for study phenotypes across sex. Significant differences in means across groups is denoted by * $p < .05$. Cohen's *d* effect size can be interpreted as small if .2–.3, medium if around .5, and large if .8+ (Cohen, 1988). Non-European ancestry includes those of African, Asian, Hispanic, mixed, or other ancestry, but were grouped together given the small sub-group size across studies due to lack of power to test all ethnic minority sub-groups (see power analyses in analysis plan section). The total sample size for MCTFR = 3,487 with a mean age of 27.2 (*SD*

Author Manuscript Author Manuscript Author Manuscript Author Manuscript

= 3.49) at the most recent assessment. The total sample size for the MN ADHD study = 621 with a mean age of 25.2 ($SD = 5.5$) at the most recent assessment. The total sample size for SSDP = 577 with a mean age of 33.2 ($SD = .95$) at the most recent assessment. The total sample size for RHC = 601 with a mean age of 24.2 ($SD = .71$) at the most recent assessment.

Table 3

Associations between Candidate Gene and Externalizing Phenotypes by Study

Association	MCTFR (N = 3,487)			MN Drug Abuse and ADHD Study (N = 610)			SSDP = 577)			RHC (N = 601)			Meta-Analyzed β (95% CI)	p-value
Nicotine (full sample)	β	SE	p	β	SE	p	β	SE	p	β	SE	p		
MAOA	.01	.03	.66	.04	.04	.37	.05	.05	.35	-	-	-	.03 (-.02, .07)	.23
DRD4	.04	.04	.30	.02	.04	.66	.01	.05	.77	-	-	-	.03 (-.02, .07)	.31
DAT1	.01	.03	.75	.02	.04	.70	.02	.04	.73	-	-	-	.03 (-.03, .06)	.46
5HTTLPR	.03	.03	.23	.01	.04	.90	.02	.04	.67	-	-	-	.02 (-.02, .06)	.28
COMT	-.01	.02	.64	-.04	.04	.28	-.01	.05	.79	-.01	.04	.89	-.02 (-.05, .02)	.35
DRD2	.01	.02	.82	-.01	.04	.79	.04	.04	.34	-	-	-	.01 (-.02, .04)	.48
Aggregate genetic risk score	.03	.03	.40	.01	.04	.76	.06	.04	.14	-	-	-	.03 (-.01, .07)	.11
Nicotine Exposed														
MAOA	.00	.03	.97	.01	.05	.92	.07	.05	.20	-	-	-	.02 (-.03, .06)	.47
DRD4	.03	.04	.39	.05	.04	.24	.01	.05	.90	-	-	-	.03 (-.02, .08)	.18
DAT1	.02	.03	.55	.00	.05	.95	.02	.05	.70	-	-	-	.02 (-.03, .06)	.49
5HTTLPR	.03	.03	.26	.01	.05	.92	-.03	.05	.53	-	-	-	.01 (-.03, .06)	.56
COMT	-.01	.02	.76	-.08	.04	.06	-.04	.05	.40	-.01	.05	.81	-.02 (-.06, .01)	.13
DRD2	.01	.02	.78	-.03	.05	.50	.05	.05	.34	-	-	-	.01 (-.02, .04)	.57
Aggregate genetic risk score	.02	.03	.59	-.02	.05	.65	.04	.05	.37	-	-	-	.02 (-.03, .06)	.49
Alcohol (full sample)														
MAOA	.03	.03	.32	.05	.05	.24	-.06	.05	.25	-	-	-	.01 (-.05, .07)	.68
DRD4	.02	.04	.68	.06	.04	.15	-.01	.04	.81	-	-	-	.02 (-.02, .07)	.31
DAT1	.03	.03	.31	-.00	.04	.96	-.04	.04	.35	-	-	-	.00 (-.04, .04)	.86
5HTTLPR	.00	.03	1.0	.04	.04	.35	.03	.04	.55	-	-	-	.02 (-.02, .06)	.37
COMT	-.01	.02	.60	-.04	.04	.38	-.05	.06	.40	.02	.04	.56	-.01 (-.04, .02)	.42
DRD2	-.01	.02	.80	.03	.04	.53	-.02	.04	.58	-	-	-	-.01 (-.04, .03)	.76
Aggregate genetic risk score	.02	.03	.49	.06	.04	.14	-.03	.04	.54	-	-	-	.02 (-.03, .06)	.47
Alcohol Exposed														
MAOA	.03	.03	.42	.06	.05	.21	-.06	.05	.23	-	-	-	.01 (-.05, .08)	.65
DRD4	.02	.04	.68	.07	.04	.11	-.01	.04	.78	-	-	-	.03 (-.02, .07)	.26
DAT1	.03	.03	.27	-.00	.04	.96	-.03	.04	.48	-	-	-	.01 (-.03, .05)	.76

Association	MCTFR (N = 3,487)			MN Drug Abuse and ADHD Study (N = 610)			SSDP = 577			RHC (N = 601)			Meta-Analyzed β (95% CI)	p-value
	β	SE	p	β	SE	p	β	SE	p	β	SE	p		
Nicotine (full sample)														
5HTTLPR	-.00	.03	.93	.04	.04		.03	.04	.57	-	-	-	.02 (-.02, .06)	.37
COMT	-.01	.02	.56	-.04	.04		-.05	.05	.29	.03	.04	.50	-.01 (-.04, .02)	.43
DRD2	-.01	.02	.77	.05	.04		-.03	.04	.51	-	-	-	-.00 (-.04, .03)	.91
Aggregate genetic risk score	.02	.03	.51	.07	.04		-.03	.04	.48	-	-	-	.02 (-.03, .07)	.45
Cannabis (full sample)														
MAOA	.01	.03	.83	.02	.05		.003	.05	.95	-	-	-	.01 (-.03, -.06)	.64
DRD4	.02	.03	.56	-.01	.04		-.03	.04	.42	-	-	-	-.00 (-.04, .04)	.96
DAT1	.06	.03	.03	.01	.04		.01	.04	.87	-	-	-	.03 (-.01, .07)	.10
5HTTLPR	-.00	.03	.87	-.01	.04		-.01	.04	.84	-	-	-	-.01 (-.05, .04)	.80
COMT	-.02	.02	.29	.00	.04		-.03	.04	.46	.04	.04	.38	-.01 (-.04, .02)	.51
DRD2	-.02	.02	.32	-.05	.04		-.02	.04	.96	-	-	-	-.03 (-.06, .01)	.13
Aggregate genetic risk score	.01	.03	.87	.00	.04		-.01	.04	.85	-	-	-	.00 (-.04, .04)	.92
Cannabis Exposed														
MAOA	-.02	.04	.69	.03	.05		.03	.06	.64	-	-	-	.01 (-.05, .06)	.83
DRD4	-.01	.04	.86	.00	.04		-.02	.05	.69	-	-	-	-.01 (-.06, .04)	.73
DAT1	.07	.03	.02	-.01	.04		-.01	.05	.90	-	-	-	.03 (-.03, .08)	.40
5HTTLPR	.01	.03	.72	-.00	.05		-.01	.05	.89	-	-	-	.00 (-.04, .05)	.87
COMT	-.03	.03	.18	.02	.04		-.03	.05	.54	.05	.05	.33	-.01 (-.04, .03)	.80
DRD2	-.03	.02	.24	-.06	.05		-.01	.05	.78	-	-	-	-.03 (-.07, .00)	.07
Aggregate genetic risk score	.00	.04	.94	.01	.04		-.003	.05	.96	-	-	-	.00 (.05, .12)	.90
Antisocial Behavior (full sample)														
MAOA	.07	.04	.04	-.05	.04		-	-	-	-	-	-	.01 (-.11, .13)	.87
DRD4	.01	.04	.80	-.03	.04		-	-	-	-	-	-	-.01 (-.07, .05)	.72
DAT1	.01	.03	.72	.05	.05		-	-	-	-	-	-	.02 (-.03, .07)	.42
5HTTLPR	.04	.03	.13	-.04	.04		-	-	-	-	-	-	.00 (-.07, .08)	.91
COMT	.01	.02	.65	-.03	.04		-	-	-	-	-	-	.00 (-.03, .04)	.91
DRD2	-.01	.02	.61	-.01	.04		-	-	-	-	-	-	-.01 (-.05, .03)	.58
Aggregate genetic risk score	.05	.03	.06	-.06	.04		-	-	-	-	-	-	-.00 (-.11, .11)	.97
Externalizing aggregate (full sample)														

Association	MCTFR (N = 3,487)			MN Drug Abuse and ADHD Study (N = 610)			SSDP = 577			RHC (N = 601)			Meta-Analyzed β (95% CI)	p-value
Nicotine (full sample)	β	SE	p	β	SE	p	β	SE	p	β	SE	p		
MAOA	.04	.03	.28	.02	.04	.59	-.04	.05	.44	-	-	-	.02 (-.02, .06)	.38
DRD4	.02	.04	.49	.01	.04	.72	-.01	.04	.82	-	-	-	.01 (-.04, .05)	.77
DAT1	.03	.03	.25	.03	.04	.54	-.01	.04	.88	-	-	-	.02 (-.02, .06)	.35
5HTTLPR	.02	.03	.44	-.00	.04	.97	.003	.04	.95	-	-	-	.01 (-.03, .05)	.62
COMT	-.01	.02	.61	-.04	.04	.36	-.01	.05	.81	-.01	.05	.87	-.02 (-.05, .02)	.36
DRD2	-.01	.02	.66	-.02	.04	.68	.01	.04	.81	-	-	-	-.01 (-.04, .02)	.61
Aggregate genetic risk score	.03	.03	.30	.01	.04	.87	.01	.05	.83	-	-	-	-.01 (-.05, .03)	.67

Note: Standardized coefficients (β), standard errors (SE) and p -values (p) are shown for main effects of candidate gene on phenotypes after accounting for age and first 10 principal components of ancestry. To correct for multiple testing ($\alpha = .05/6$ candidate genes), a threshold of $p < .008$ was established to reach statistical significance, however for clarity of presentation, **all p -values of .05 or less are shown in bold**. Meta-analyzed β was calculated by weighting each individual effect size by the inverse of its variance using a random effects model via the Comprehensive Meta-Analysis 2.0 software (Borenstein et al 2005); see the Analysis Plan for more detail.

Table 4

Associations between Candidate Gene and Externalizing Phenotypes by Study: Results for those with European Ancestry Only

Association	MCTFR (N = 2,964; 85% of sample)			MN Drug Abuse and ADHD Study (N = 521; 85% of sample)			SSDP (N = 302; 52% of sample)			RHC (N = 443; 74% of sample)			Meta-Analyzed β (95% CI)	p-value
	β	SE	p	β	SE	p	β	SE	p	β	SE	p		
Nicotine (full sample)														
MAOA	.01	.03	.80	.02	.05	.64	.06	.06	.39	-	-	-	.02 (-.03, .07)	.40
DRD4	.05	.04	.16	.03	.04	.56	.02	.06	.70	-	-	-	.04 (-.01, .09)	.16
DAT1	.02	.03	.60	.03	.04	.46	-.01	.06	.79	-	-	-	.02 (-.03, .06)	.40
5HTTLPR	.04	.03	.19	.01	.04	.76	.08	.06	.15	-	-	-	.04 (-.01, .08)	.11
COMT	-.01	.02	.55	-.06	.05	.15	.02	.06	.78	.01	.05	.86	-.01 (-.04, .02)	.51
DRD2	.01	.02	.66	.01	.04	.84	.07	.06	.28	-	-	-	.02 (-.02, .05)	.39
Aggregate genetic risk score	.02	.03	.50	.02	.05	.63	.09	.06	.12	-	-	-	.03 (-.02, .08)	.19
Nicotine Exposed														
MAOA	-.01	.04	.84	.01	.05	.91	.07	.05	.20	-	-	-	.02 (-.03, .07)	.50
DRD4	.05	.04	.19	.05	.05	.29	.01	.05	.90	-	-	-	.04 (-.01, .09)	.14
DAT1	.02	.03	.46	.02	.05	.76	.02	.05	.70	-	-	-	.02 (-.03, .07)	.38
5HTTLPR	.03	.03	.31	.01	.05	.88	-.03	.05	.53	-	-	-	.01 (-.03, .06)	.56
COMT	-.01	.02	.63	-.09	.05	.05	-.04	.05	.40	-.01	.05	.92	-.02 (-.05, .01)	.19
DRD2	.01	.02	.76	-.01	.05	.78	.05	.05	.34	-	-	-	.01 (-.02, .05)	.48
Aggregate genetic risk score	.01	.04	.77	-.01	.05	.83	.10	.06	.10	-	-	-	.02 (-.03, .08)	.41
Alcohol (full sample)														
MAOA	.04	.03	.23	.05	.05	.32	-.07	.07	.30	-	-	-	.03 (-.102, .08)	.23
DRD4	.02	.04	.64	.05	.04	.23	.04	.06	.49	-	-	-	.04 (-.01, .09)	.16
DAT1	.04	.03	.19	.01	.04	.75	-.07	.06	.24	-	-	-	.02 (-.03, .06)	.49
5HTTLPR	.01	.03	.80	.04	.04	.34	.05	.06	.41	-	-	-	.03 (-.02, .07)	.27
COMT	-.01	.02	.64	-.06	.05	.17	-.02	.06	.78	.04	.04	.40	-.01 (-.04, .02)	.63
DRD2	-.01	.02	.83	.04	.05	.39	-.02	.06	.70	-	-	-	-.01 (-.04, .03)	.80
Aggregate genetic risk score	.03	.03	.30	.06	.04	.16	-.02	.06	.77	-	-	-	.03 (-.01, .08)	.15
Alcohol Exposed														
MAOA	.04	.03	.29	.05	.05	.27	-.08	.07	.27	-	-	-	.03 (-.02, .08)	.24

Association	MCTFR (N = 2,964; 85% of sample)			MN Drug Abuse and ADHD Study (N = 521; 85% of sample)			SSDP (N = 302; 52% of sample)			RHC (N = 443; 74% of sample)			Meta-Analyzed β (95% CI)	p-value
	β	SE	p	β	SE	p	β	SE	p	β	SE	p		
Nicotine (full sample)														
DRD4	.02	.04	.63	.06	.05	.17	.04	.06	.53	-	-	-	.04 (-.02, .09)	.19
DAT1	.04	.03	.16	.01	.05	.83	-.06	.06	.34	-	-	-	.02 (-.03, .06)	.45
5HTTLPR	.00	.03	.87	.04	.05	.37	.06	.06	.37	-	-	-	.02 (-.03, .07)	.44
COMT	-.01	.02	.61	-.07	.05	.14	-.02	.06	.72	.04	.04	.37	-.01 (-.04, .02)	.59
DRD2	-.01	.02	.69	.06	.05	.21	-.01	.06	.80	-	-	-	-.00 (-.04, .03)	.95
Aggregate genetic risk score	.03	.03	.32	.07	.04	.11	-.01	.06	.82	-	-	-	.04 (-.01, .08)	.10
Cannabis (full sample)														
MAOA	.02	.03	.63	.02	.05	.67	.01	.07	.88	-	-	-	.02 (-.03, .07)	.44
DRD4	.03	.04	.42	-.01	.04	.78	-.01	.05	.93	-	-	-	.01 (-.04, .05)	.84
DAT1	.07	.03	.01	-.00	.04	.92	-.04	.05	.40	-	-	-	.03 (-.01, .07)	.18
5HTTLPR	.01	.03	.64	.01	.05	.76	-.01	.06	.88	-	-	-	.01 (-.04, .05)	.77
COMT	-.02	.02	.27	-.01	.05	.78	.08	.05	.13	.03	.05	.63	-.00 (-.04, .03)	.87
DRD2	-.02	.02	.35	-.02	.05	.60	-.04	.05	.42	-	-	-	-.02 (-.06, .01)	.20
Aggregate genetic risk score	.02	.04	.51	.01	.04	.90	.01	.06	.82	-	-	-	.01 (-.04, .06)	.58
Cannabis Exposed														
MAOA	-.00	.04	.93	.03	.05	.57	.01	.08	.82	-	-	-	.01 (-.05, .07)	.69
DRD4	-.00	.04	.99	-.01	.05	.88	.02	.06	.68	-	-	-	.00 (-.05, .06)	.97
DAT1	.09	.03	.006	-.03	.05	.56	-.04	.06	.45	-	-	-	.04 (-.00, .09)	.07
5HTTLPR	.02	.03	.46	.02	.05	.68	.003	.07	.96	-	-	-	.02 (-.03, .07)	.46
COMT	-.04	.03	.18	.02	.05	.76	.08	.06	.13	.07	.06	.23	.00 (-.04, .05)	.91
DRD2	-.03	.03	.21	-.03	.05	.52	-.06	.06	.30	-	-	-	-.04 (-.08, .01)	.14
Aggregate genetic risk score	.02	.04	.71	.01	.05	.75	.03	.07	.68	-	-	-	.02 (-.04, .07)	.52
Antisocial Behavior (full sample)														
MAOA	.07	.03	.03	-.06	.05	.21	-	-	-	-	-	-	.04 (-.02, .09)	.17
DRD4	.01	.04	.78	-.03	.04	.39	-	-	-	-	-	-	-.01 (-.05, .02)	.43
DAT1	.02	.03	.60	.07	.05	.20	-	-	-	-	-	-	.03 (-.02, .08)	.20
5HTTLPR	.05	.03	.06	-.00	.04	.98	-	-	-	-	-	-	.03 (-.02, .08)	.18
COMT	.01	.02	.66	-.07	.05	.17	-	-	-	-	-	-	-.00 (-.04, .04)	.96

Association	MCTFR (N = 2,964; 85% of sample)			MN Drug Abuse and ADHD Study (N = 521; 85% of sample)			SSDP (N = 302; 52% of sample)			RHC (N = 443; 74% of sample)			Meta-Analyzed β (95% CI)	p-value
Nicotine (full sample)	β	SE	p	β	SE	p	β	SE	p	β	SE	p		
DRD2	-.01	.02	.84	-.03	.04	.44	-	-	-	-	-	-	-.01 (-.05, .02)	.43
Aggregate genetic risk score	.06	.03	.04	-.05	.04	.15	-	-	-	-	-	-	.02 (-.03, .07)	.40
Externalizing aggregate (full sample)														
MAOA	.04	.04	.23	.02	.05	.75	-.03	.07	.72	-	-	-	.02 (-.03, .08)	.44
DRD4	.03	.04	.37	.02	.04	.71	.01	.05	.90	-	-	-	.02 (-.03, .07)	.39
DAT1	.05	.03	.14	.04	.05	.42	-.05	.05	.35	-	-	-	.03 (-.02, .07)	.24
5HTTLPR	.03	.03	.24	.03	.04	.57	.07	.06	.30	-	-	-	.04 (-.01, .08)	.11
COMT	-.01	.02	.57	-.07	.05	.13	.05	.06	.37	.01	.05	.84	-.01 (-.04, .02)	.56
DRD2	-.01	.02	.80	-.00	.04	.96	.000	.06	1.0	-	-	-	.02 (-.03, .07)	.39
Aggregate genetic risk score	.04	.04	.19	.02	.04	.71	.04	.07	.55	-	-	-	.03 (-.02, .08)	.23

Note: Standardized coefficients (β), standard errors (SE) and p-values (p) are shown for main effects of candidate gene on phenotypes after accounting for age and first 10 principal components of ancestry. To correct for multiple testing ($\alpha = .05/6$ candidate genes), a threshold of $p < .008$ was established to reach statistical significance, however for clarity of presentation, **all p-values of .05 or less are shown in bold**. Meta-analyzed β was calculated by weighting each individual effect size by the inverse of its variance using a random effects model via the Comprehensive Meta-Analysis 2.0 software (Borenstein et al 2005); see the Analysis Plan for more detail.